True. Many of our advances in longevity research & development are published months, often years, and sometimes more than a decade after they happen

It'll be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human wired.com/story/longevity-st…

And of course by “reverse aging” I mean epigenetic restoration by ER-100

It's out!

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

Two FDA-approved drugs just produced one of the largest lifespan extensions in mice • Trametinib: 7.2% (f), 10.2% (m)
 • Rapa: 17.4% (f), 16.6% (m)
 • Both: 29% (f), 27% (m) The drugs target different aspects of/insulin/TOR to mimic fasting 🚀 
nature.com/articles/s43587-0…

You don’t need extreme step counts. 7,000 steps per day already associates with dramatically lower mortality risk join.lifespan.com/ka6s4u6r

Declining kidney function is the most overlooked cause of death Only 55,000 US deaths/yr are attributed to it, yet ~37M have chronic kidney disease & this speeds heart disease, infection, frailty & early death. Markers to watch: Cystatin C & urine albumin

Congrats Adiv and David! 🎉

Aging is not wear and tear. It's reprogrammable

New paper by @BKennedy_aging finds that supplement users have a significantly younger Age Delta, which is not the case for medication users What were the supplements? 1. Alpha-ketoglutarate (AKG), carotenoids, calcium, CoQ10, curcumin, D3, and NAD boosters were associated with lower Age Delta 2. The paper "shows for the first time that an inexpensive, non-invasive, saliva-based biological age test can be a powerful tool to conduct population research and uncover relationships between lifestyle, medications, and supplement use" 3. Heavy supplement use was neither beneficial nor harmful 4. However, older men appeared to respond better to AKG than older women 5. AKG was associated with lower Age Residual regardless of weight, weekly exercise, or alcohol intake, with slightly larger benefits seen in those who exercise more often 6. Traditionally, doctors view polypharmacy (more than one treatment) as a liability to be avoided. However, "it is more likely that polypharmacy is a consequence and not a cause of age-related morbidity." 7. Several observational studies find combining two drugs reduces all-cause mortality. The potential risks and harms of supplement polypharmacy are less understood. 8. In this cohort almost 11% of the participants were taking more than 5 supplements, yet their health condition was excellent and higher supplement use was not associated with older biological age, suggesting that supplement combinations are well tolerated Useful study. Well done @BKennedy_aging and team. Food for thought 🤔

Join us!

Thank you for all your support! Early access to Season 2 @ lifespan.com

Great to be back! m.youtube.com/watch?v=rXLCug…